Jim Cramer on Johnson & Johnson: "Their Core Pharma Business is Roaring"

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer picked for his fantasy stock portfolio. Cramer made some positive comments about the company, as he commented:

“JNJ’s up roughly 23% year to date. I couldn’t believe it, I saw it was like 180. It was amazing. Weak action throughout most of the healthcare, not affecting these people. Their core pharma business is roaring. Terrific oncology franchise, medical devices really strong now. That’s why JNJ keeps putting up good numbers, and they don’t have that lawsuit as much as, it used to be front and center. Not anymore. Now both the Eagles and JNJ do come with some risks… JNJ, the company’s still not quite clear of all the talc litigation headaches. But at the end of the day, I expect the overall quality of both franchises to win out.”

Johnson & Johnson (NYSE:JNJ) develops and markets pharmaceuticals, medical devices, and vision care products. The company’s solutions include therapeutic treatments, surgical technologies, and eye health solutions.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.